Economic evaluation of treatments for respiratory disease.
Considerable quantities of health service resources are being devoted to tackling the problems posed by respiratory diseases and this can be expected to continue as the prevalence of such diseases increases.  This paper provides an assessment of the most efficient use of these healthcare resources by reviewing the literature on economic evaluation relating to interventions in the field of respiratory medicine.  Currently, this literature largely comprises cost-minimisation studies of both management and educational interventions.  Asthma educational interventions, whether targeted at adults or children, appear to be effective in improving patient self-management and adherence to medications, and appear to be associated with a lower overall use of healthcare resources.  In terms of management interventions the overall picture is rather less clear although there is some support for the greater efficiency of patient administration of beta-adrenergic agonists by metered dose inhalers over therapist-administered up-draft nebulisation.  Two features of respiratory disease make evaluation in this field somewhat unusual: there are alternative methods of delivering therapy to patients, which makes patient compliance an important issue, and since most respiratory diseases are chronic conditions the long-term effectiveness of interventions must be assessed.  The scarcity of cost-effectiveness and cost-utility studies in this field may, in part, reflect the difficulties of measuring outcomes in respiratory disease.
Health Economics Research Group, Brunel University, Uxbridge, Middlesex, England.
S
S
Bryan
M J
MJ
Buxton
D003365:Costs and Cost Analysis; D006801:Humans; D010353:Patient Education as Topic; D012138:Respiratory Therapy / Q000191:economics*; D012140:Respiratory Tract Diseases / Q000191:economics / Q000517:prevention & control / Q000628:therapy; D016896:Treatment Outcome